Abstract
Pancreas transplantation is, at present, the only curative treatment for type-1 diabetes that maintains normoglycemia thus avoiding complications arising from poor glycemic control. Despite its great benefits, the number of pancreas transplants has decreased significantly since its inception in the late 1960s, largely due to demographic changes and the consequent suboptimal quality of donors. The selection criteria for pancreas donors mainly depend on morphological variables such as fatty infiltration, fibrosis, or edema, as well as both functional (amylase and lipase) and clinical variables of the donor. However, the final criterion in the decision-making process is the somewhat subjective assessment of a trained surgeon. That being said, the recent incorporation of graft perfusion machines into clinical practice seems to be changing the work dynamics of the donor organ retrieval team, facilitating decision-making based on objective morphological and functional criteria. Normothermic perfusion using perfusate with supplemental oxygen replicates near physiological parameters thus being a promising strategy for organ preservation. Nevertheless, optimum perfusion parameters are difficult to establish in pancreas transplantation given its complex vascular anatomy combined with an intrinsically low blood flow. The objective of this work is to analyze the results published in the recent literature relating to the considerations of ex-vivo normothermic graft perfusion machines and their usefulness in the field of pancreas transplantation.
Introduction
Pancreas transplantation is currently the only treatment alternative to restore insulin independence in patients with type-1 diabetes, ameliorate the course of the secondary complications of the disease and improve both patient survival and quality of life (1). A whole pancreas may be transplanted alone, simultaneously or following an earlier kidney transplant. Simultaneous kidney-pancreas transplantation constitutes the therapy of choice for diabetic patients with end-stage renal disease, accounting for 86% of total pancreas transplant procedures (2). In addition, pancreatic islet transplantation provides a less invasive option to whole pancreas transplantation but requires multiple donor pancreases to achieve insulin independence (3).
The long-term outcomes of pancreas transplantation have significantly improved over time and the development and progression of secondary diabetic complications have been reduced or even reversed after a successful transplant (4). Despite these advances, the annual number of pancreas transplants is declining, even though the prevalence of diabetes has increased (5). At present, one of the limiting factors for whole organ pancreas and islet transplantation programs is the scarcity of suitable donors. This is due to the progressive aging of the donor population, the increasing number of obese donors, and the growing levels of donation from circulatory death (DCD) donors (6). On this basis, the “ideal” pancreas is difficult to find and transplant units have progressively broadened the standard criteria donors to include these marginal, high-risk organs. Such extended criteria donors' grafts are more vulnerable to ischemic injury and often associated with an expanded rate of early allograft dysfunction (7).
Static cold storage of pancreas grafts: Reaching the limits of preservation in marginal donors
The organ preservation process is an essential part of transplantation to maintain function of the organ and tissue during storage. Preservation of the pancreas is critical to prevent the two major early complications of pancreas transplant, namely thrombosis and graft pancreatitis. These complications are causes of graft loss in the postoperative period and can occur in 25–50% of cases (8). The standard method to preserve human pancreas is hypothermic preservation by static cold storage (SCS). Once the organ is harvested, an immediate flush is performed with a cold preservation fluid in order to quickly cool down the organ through the elimination of remaining blood and vascular uptake of the solution. This provides an optimal environment for subsequent storage of the organ on ice in the same solution and transportation in a cooler until its implantation in the recipient. This technique is currently the standard method for pancreas preservation because of its simplicity, low costs, and favorable outcomes for high quality organs (9). However, its use is limited because of the increasing number of marginal donor organs.
During the ischemic phase of SCS, the deficiency of oxygen results in the lack of enough adenosine triphosphate (ATP) generation for continued cellular function, resulting in downstream impacts and accumulation of toxic metabolites that, in turn, exacerbate cell injury and damaging pathways after the reperfusion stage. Generation of ROS upon restoration of blood flow in the recipient promote endothelial dysfunction, and local inflammatory responses (10). Even so, although cold ischemia itself does not prevent the chemical processes that cause the ischemic injury during the preservation period, hypothermia still has a crucial role in organ preservation through the slowing down of metabolism.
Preservation solutions for SCS have also been developed to counteract ischemic injury (11). The choice of pancreas cold preservation solutions for SCS varies between countries (12).
Moving toward ex vivo machine perfusion for advanced preservation and conditioning of the pancreas graft
Ex vivo machine perfusion (EVMP) has provided benefits over SCS in other organ transplants (8). It consists of a pump-generated flow through the organ in a circuit allowing recirculation of a preservation solution through the vasculature at various temperatures. The continuous perfusion promotes the delivery of oxygen and nutrients to the parenchyma together with the removal and “washout” of noxious metabolites. Besides improving preservation, EVMP may allow in vivo measurement in the perfusate of functional and biochemical parameters of the graft, providing a tool for selection and even maintenance of transplantable grafts, an especially interesting factor when using marginal grafts (13). In this context, SCS does not allow the extension of the donor pool as the decision of accepting the organ for transplantation is taken after visual macroscopic assessment, bringing us a step closer to the era of dynamic preservation strategies. Hence, the purpose of this review is to update the current knowledge of EVMP techniques with special consideration to the little explored field of ex vivo normothermic machine perfusion (EVNMP) for pancreas grafts. While technically more complex, the principles of EVNMP are to maintain physiological conditions. In this setting, this technology has been demonstrated to be clinically beneficial in the context of immediate graft function in organs such as the kidney, the liver, and the lung (14–16). The review will provide an overview of the fundamentals of current pancreatic EVNMP and will discuss the future use of this technique in addressing the imbalance between the current donor pancreas demand and supply by enabling the restoration of damaged pancreas and subsequently improve graft function.
The objectives set in the development of EVMP lie in the selection of useful parameters for the acceptability of the grafts and the improvement of their quality. In the field of pancreas transplantation there is still further work to be done, since some EVMP protocols cannot be directly applied to the pancreas as it is significantly more vulnerable to injury than other abdominal organs. In fact, the stricter donor selection criteria for transplantation results in a much higher discard rates of donor pancreas. The pancreas has an intrinsically low blood flow with complex vascular anatomy and is highly sensitive to ischemic injury during both organ retrieval and preservation causing a negative impact on the microcirculation of the grafts. In this sense, high perfusion pressure, such as that used in the liver and kidney EVMP, can cause acinar necrosis, edema formation and endothelial injury, which are recognized risk factors for early graft pancreatitis and thrombosis. On the contrary, if the pressure is too low, perfusate blood flow will not be appropriate for an effective perfusion of the microvasculature and an adequate oxygenation and nutrient supply (17).
As detailed below, hypothermic and normothermic perfusion machines have currently emerged as innovative procedures for advanced organ preservation and conditioning in clinical practice.
Ex vivo hypothermic machine perfusion
Ex vivo hypothermic machine perfusion (EVHMP) implies the recirculation of cooled preservation solution through the vascular system of the organ in either a continuous or a pulsatile flow. The maintenance of the donor organ on a device at low temperatures is meant to prevent ATP depletion reducing the deleterious effects of ischemia and reperfusion injury. This is one of the advantages that have made EVHMP become an alternative to SCS, particularly in kidney and liver preservation (18, 19). Another advantage is that the temperature can be accurately regulated to rest in the preferable range of 4–8°C. In SCS on ice, temperatures frequently fall around or below 0°C, inducing crystal formation within the cytoplasm and thus resulting in more severe tissue injury upon reperfusion (20). Furthermore, compared to SCS, EVHMP can expand the donor pool by enabling the surgeon to accept marginal donors and those with longer preservation times. On the contrary, it does not allow the functional assessment of the graft under hypothermic conditions (21).
To date, there are no publications reporting clinical pancreas transplant using EVHMP strategies and most studies have been undertaken using animal models or discarded human pancreata. All these pre-clinical studies have been performed at low perfusion pressures thus indicating low pressures as a safe condition for pancreas EVHMP. However, some limitations of these studies are that they are mainly based on histological findings and the lack of post-transplant evaluation. In these cases, a normothermic reperfusion could be used to mimic the physiological environment of transplantation and allow an optimal assessment of organ viability.
Ex vivo normothermic machine perfusion
Ex vivo normothermic machine perfusion (EVNMP) has been developed as a resuscitation tool for the organ after a period of SCS and is employed for short space of time i.e., while the recipient is being prepared for transplant. Subsequently, the graft is provisionally returned to SCS until transplantation (22).
Compared to EVHMP, EVNMP allows a complete functional assessment of the graft under physiologic conditions, usually between 34°C and 39°C. This fact makes EVNMP an invaluable tool for ex vivo functional analysis as well as the technique can also be applied to extend the storage periods, which may help facilitate long-distance transportation. Another unique advantage is the ability to pretreat the organ to deliver therapeutic agents ex vivo prior to transplantation in the recipient (23).
Normothermic organ preservation demands a physiological environment with appropriate oxygen, nutrition, and metabolic substrates to replace consumed cellular energy resources. Additionally, to reduce oxidative damage, the perfusate solution needs to stabilize electrolyte balance and cell fluid content to decrease edema and reduce free radical peroxide scavengers (24). In clinical practice, the most used perfusate solution contains a red cell-based solution enriched with nutrients and also containing physiological buffers and supplementary constituents. Normothermic storage with whole blood cells-based solutions have been also investigated, although it has been demonstrated that the blood may contain different factors, such as antibodies, clotting factors, activated leukocytes and thrombocytes, which may aggravate ischemia reperfusion injury. During this process, inflammatory mediators are generated together with the activation of complement cascades (25). Subsequently, leukocyte-depleted blood and plasma-free based perfusates have been well-established in both pre-clinical and clinical studies.
Hosgood et al. were the first to use EVNMP to assess kidney viability pre-transplantation. In this study, a short period of normothermic perfusion was applied to a discarded kidney before its transplantation (26). Then, in a small clinical trial, 1 hour of normothermic oxygenated perfusion permitted resuscitation and evaluation of 10 declined DCD kidneys using a quality score based on gross appearance, renal blood flow and total urine output (14). Meanwhile, recent results from a clinical trial on 31 discarded livers demonstrated the feasibility of EVNMP and the successful transplantation of 71% of perfused livers without any incidence of primary non-function in addition to a 100% 90-day patient and graft survival (27).
Ex vivo normothermic machine perfusion parameters to enable pancreas graft quality and viability
In the field of pancreas transplantation, normothermic preservation technologies still await a breakthrough. A number of studies have been reported, either experimental or pre-clinical, and the vast majority used a deficient number of pancreas and are mainly based on histological findings and poor biochemical analysis. Because of this, there is a need to establish the optimal assessment parameters to determine graft quality and viability.
The first investigation of normothermic perfusion in the pancreas was reported in 1926 by Babkin and Starling using isolated dog pancreas (28). Other systems were subsequently developed for different animal models to assess viability and function after various durations and storage conditions (29–44). It has not been until the last 10 years (Tables 1, 2) that interest in the subject has been reactivated owing to the critical shortage in organ donation and the fact that a greater number of extended criteria donors are used for transplantation. In 2017, the first study in porcine pancreas established a model of perfusion in an oxygenated roller pump with and without addition of the kidney to the DBD pancreas as a dialysis organ (45). The perfusate consisted of autologous whole blood incorporating cephazolin, epoprostenol sodium, and heparin. Despite minimal cold ischemia time (CIT), stable perfusion and maintenance of acid-base homeostasis, exocrine pancreatic tissue displayed acinar damage, inflammation, and thrombosis while islets cells remained relatively spared. The explanation of the issues highlighted by the EVNMP groups was that, as the perfusion solution is continuously recycled around the circuit, the levels of proteolytic enzymes produced by the pancreas increase progressively throughout perfusion. The use of whole blood as perfusate must also be taken into consideration as it could potentially exacerbate inflammatory response and tissue damage. Likewise, perfusion pressure in this study was 70–80 mmHg, which could be considered too high for the pancreatic organ and thus a contributor to the acinar injury.
Table 1
| Perfusion characteristics | Arterial parameters | Studies and analysis | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Author [ref] (Year) | Model (strain; weight) n | Donor model (DBD/DCD) | Mean pancreatic weight | CIT | Perfusion device (pulsatile/ non-pulsatile) | Perfusion time | Perfusate (volume) (protease inhibitor; colloid) | Dialysis circuit | % Oxygen | Arterial pressure | Arterial bloodflow rate | Samples | Histopathological analysis | Blood gas analysis | Biochemical analysis | Transplant |
| Kuan (45) (2017) | Pig (domestic white; 40-50kg) n = 4 (2 pancreases alone, 2 pancreas + kidney) | DBD | NS | 34 ± 7.78 min | SARNS 8000 extracorporeal roller pump (3M, St. Paul, MN, USA), Baby-RX venous reservoir and membrane oxygenator (Terumo, Ann Arbor, MI, USA), and water bath temperature regulator (pulsatile) | 4 h for pancreas alone, 2 h for pancreas + kidney | Autologous whole blood, cephazolin, epoprostenol sodium, heparin (1.8–2 L) (no; no) | Yes (addition of the porcine kidney in 2 of the animals) | NS | 70–80 mmHg for pancreas alone, 90–100 mmHg for pancreas + kidney | 200 ml/min | Perfusate, blood, pancreas biopsies and urine | Gross appearance Hematoxylin and eosin stain | Yes | Biochemical analysis of blood samples not performed due to haemolysis Perfusion dynamics Endocrine function under glucose stimulation | No |
| Kumar (46) (2018) | Pig [Yorkshire landrace; 45-55 kg) n = 13 (9 pancreases control group (50mmHg), 4 pancreases low-pressure group (20 mmHg)] | DCD | NS | 127 min (control group), 136 min (low pressure group) | Affinity CP Centrifugal pump and Minimax Plus oxygenation System (Medtronic Inc., (Minneapolis, MN, USA) with a thermostatic water-based heat exchanger unit (non-pulsatile) | 2–4 h (control group), 4 h (low pressure group) | Autologous whole blood, cefuroxime, epoprostenol sodium (1.5 L) (no; no) | NS | NS | 50 (control group; high), 20 (low pressure group). From other studies the group stablished that 50 mmHg of pressure was optimal to prevent edema in the graft. | 141 ml/min (control group), 40 ml/min (low-pressure group) | Perfusate, pancreatic juice, blood and pancreas biopsies | Hematoxylin and eosin stain Immunohistochemistry (caspase-3, M30 cytodeath and ATP synthetase) | Yes | Exocrine function in perfusate through amylase and lipase levels and production of pancreatic juice Endocrine function under glucose stimulation Measure of hemoglobin, lactate, glucose, potassium, sodium and chloride | No |
| Hamaoui (47) (2018) | Pig (NS; NS) n = 10 | DCD | NS | 3–7 h | Waters Medical RM3 Machine Perfusion Unit with oxygenator (Waters Medical Systems, Rochester, MN) (non-pulsatile) | 2 h | Autologous whole blood:saline mixture (3:1) supplemented with NaH2CO3 (NS) (no; no) | NS | 95% | 45 mmHg | 40–70 ml/min/100 g | Pancreatic exocrine and duodenal secretions, pancreas biopsies | Hematoxylin and eosin stain | Yes | Exocrine function in pancreatic exocrine and duodenal secretions through amylase Endocrine function (insulin levels) under glucose stimulation Levels of tissue lactate | No |
| Ogbemudia (48) (2021) | Pig (domestic; 50–70 kg) n = 13 (4 pancreases 6 h SCS + 1 h EVNMP; 4 pancreases 6 h UW-EVHMPO + 1 h EVNMP; 5 pancreases 6 h IGL2-EVHMPO + 1 h EVNMP) | DCD | NS | 9h (3h + 6h) | Deltastream DP3 diagonal pump (MEDOS Medizintechnik AG, Stolberg, Germany), oxygenator and heat exchanger unit (MEDOS HILITE 2800 LT TM) (pulsatile) | 1 h | Autologous red blood cells and plasma without leukocytes, coamoxiclav, heparin (800 ml) (no; no) | NS | 95% | 40 ± 8 mmHg | 67 ± 43 ml/min (IGL2-EVHMPO group), 137 ± 86 ml/min (UW-EVHMPO group), 46 ± 32 ml/min (SCS group) | Perfusate, pancreas biopsies | Gross appearance | Yes | Water mass in graft samples Lipase, amylase, lactate, and lactate dehydrogenase (LDH) in perfusate Endocrine function under glucose stimulation | No |
| Mazilescu (49) (2022) | Pig [Yorkshire; 30 kg (7 pigs, EVNMP), 40 kg (3 pigs EVNMP+Tx)] n = 10 (7 pancreases for 6 h EVNMP, 3 pancreases for 3 h EVNMP+Tx) | NS | 143.9 ± 17.6 g after retrieval, 201.4 ± 32.1 g after perfusion | NS | S3 heart-lung machine and neonatal cardiopulmonary bypass equipment consisting of a centrifugal pump, an oxygenator (Sorin Group Inc., Markham, Canada) with an addition of heat exchanger (non-pulsatile) | 6 h EVNMP, or 3 h EVNMP +Tx | Ringer's lactate, STEEN Solution (XVIVO Perfusion AB, Goteborg, Sweden), washed leukocyte-filtered erythrocytes, double reverse osmosis water, sodium bicarbonate, calcium gluconate, heparin, aprotinin (NS) (aprotinin, albumin) | Yes | 95% | 25 mmHg | 120 ± 21 ml/min initially, 101 ± 15 ml/min toward end of perfusion | Perfusate, pancreatic juice, duodenal samples and pancreas biopsies | Hematoxylin and eosin stain | Yes | LDH, Glucose, insulin, C-peptide and bicarbonate concentration Inflammatory cytokines Mild hemolysis but possible assessment of amylase Endocrine function under glucose stimulation | Yes (n = 3), diabetes was induced by pancreatectomy in recipients prior to Tx |
Experimental EVNMP studies in animal models.
DBD, Donation after Brain Death; DCD, Donation after Circulatory Death; CIT, Cold Ischemia Time; Tx, Transplantation; NS, Not Specified; EVNMP, Ex Vivo Normothermic Machine Perfusion; EVHMPO, Ex Vivo Oxygenated Hypothermic Machine Perfusion.
Table 2
| Perfusion characteristics | Arterial parameters | Studies and analysis | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Author [ref] (Year) | Donor type (DBD/DCD) n | CIT | Perfusion device (pulsatile/non-pulsatile) | Perfusion time | Perfusate (volume) (protease inhibitor; colloid) | Dialysis circuit | % Oxygen | Arterial pressure | Arterial bloodflow rate | Samples | Histopathological analysis | Blood gas analysis | Biochemical analysis |
| Barlow (50) (2015) | 3 DBD + 1DCD n = 5 (1 excluded due to elevated CIT) | 13–18 h | Customized pediatric cardiopulmonary bypass technology developed for kidney EVNMP (Medtronic Inc.) with an organ chamber, venous reservoir, Biopump 560 centrifugal blood pump, oxygenator, and a heat exchanger (Chalice Medical Ltd, United Kingdom) (non-pulsatile) | 1–2 h | Blood-based perfusate mixture (donor ABO-compatible red blood cells) diluted with Gelofusine, additives (sodium bicarbonate, mannitol, glucose, heparin) (NS) (NS; Gelofusine) | NS | 95 % | 50–55 mmHg | 35 ± 2.8 mL/min/100 g | Perfusate, pancreas biopsies | Gross appearance Hematoxylin and eosin stain in biopsies | Yes | Exocrine function in perfusate through amylase and lipase levels Endocrine function (insulin levels) under glucose stimulation |
| Hamaoui (47) (2018) | NS n = 3 (1 excluded due to massive edema) | 26.8 and 56 h respectively | Waters Medical RM3 Machine Perfusion Unit with oxygenator, heat exchanger and pump head (Waters Medical Systems, Rochester, MN) (non-pulsatile) | 2 h | Krebs-Henseleit buffer-based solution, NaH2CO3 (NS) (no; no) | NS | 95 % | 40 and 32 mmHg | 32.2 and 49.8 mL/min/100 g, respectively | Pancreatic exocrine and duodenal secretions, pancreas biopsies | Gross appearance Hematoxylin and eosin stain in biopsies | NS | Exocrine function in perfusate through amylase levels Endocrine function (insulin levels) under glucose stimulation |
| Nassar (51) (2018) | DBD n = 3 | 4 h | Customized liver perfusion device. Centrifugal pump, oxygenator, and heater exchanger (Medtronic Inc.) with an added Sarns 8000 Roller Pump (Terumo, Ann Arbor, MI, USA) (non-pulsatile) | Two grafts perfused for 6 h, one for 12 h | Packed red blood cells and plasma 1:3 ratio (NS) (NS; NS) | NS | NS | 60 mmHg | 55 mL/min/100 g | Perfusate, pancreas and duodenal secretions, pancreas biopsies | Chromogranin A stain of pancreatic exocrine parenchyma Hematoxylin and eosin stain of pancreas acinus and islets | NS | Exocrine biochemical evaluation trough bicarbonate levels in the duodenum C-peptide levels |
Experimental EVNMP studies in discarded human pancreata.
DBD, Donation after Brain Death; DCD, Donation after Circulatory Death; CIT, Cold Ischemia Time; NS, Not Specified; EVNMP, Ex Vivo Normothermic Machine Perfusion.
The same group directly studied the effects of EVNMP testing two different pressure perfusions in a porcine DCD pancreata model (46). In this study, an oxygenated non-pulsatile pump was used with a whole blood-based perfusate to which heparin was added to reduce coagulation. The control group was perfused at 50 mmHg and was compared to an experimental group of “low pressure” grafts perfused at 20 mmHg. Both pancreatic blood flow and pressure remained stable, but control grafts achieved a mean blood flow of 140 ml/min, while the low-pressure group achieved a blood flow of only 40 ml/min, indicating a worse perfusion. All grafts showed evidence of oxygen absorption and cellular viability, as corroborated with immunohistochemistry. Both endocrine and exocrine functionality were preserved, but amylase levels were significantly lower at all time points in the low-pressure group compared with controls. Notwithstanding, cell viability and ATP synthetase stain showed an improved score grade in the low-pressure group. This is the only study on EVNMP in porcine pancreas that measures ATPase activity, a marker of viability which has been related to better transplantation outcome (52). Despite some controversy in the results, the authors suggest low pressure perfusion as an improved method for graft preservation during EVNMP.
Hamaoui et al. (47) and Ogbemudia et al. (48) developed a normothermic hemoperfusion circuit for the pancreas used in parallel to the design of the EVHMP porcine model with the aim of studying the feasibility assessment of the graft. However, as this is a different concept than the application of “pure” ex vivo normothermia for reversing ischemia injury, these results should be carefully analyzed.
A recent study has demonstrated the safety of pancreas transplantation after EVNMP in a porcine model using an oxygenated non-pulsatile pump in combination with a dialysis circuit (49). The perfusate consisted of STEEN solution. The solution included human serum albumin which provides an optimal colloid osmotic pressure and dextran to preserve the endothelium from excessive leukocyte interaction. In addition, washed-leukocytes-filtered erythrocytes, sodium bicarbonate, heparin and aprotinin were added. Seven out of ten pancreas were subjected to 6 h of EVNMP. The grafts showed stable perfusion parameters, active metabolism, homeostasis, and only mild graft injury assessed through histology. Initially, arterial blood flow rate was around 120 ml/min. and slightly decreased to 101 ml/min, likewise maintaining high levels which allow for a better perfusion of the graft. Cytokine release during EVNMP in the perfusate showed an increase in IL-6 pro-inflammatory and TGF-β1 and TGF-β2 anti-inflammatory cytokines although high levels of cytokines were found in the dialysate, which probably served to minimize the inflammation and graft injury during EVNMP. In this study, glucagon stain was used to highlight preserved islets cells. To demonstrate the reliability of the perfusion system, the remaining three pancreases were subjected to 3 h of perfusion prior to transplantation and the recipients were then observed for 48–72 h post-transplantation. EVNMP grafts had normal function based on histological findings and maintained physiologic glucose levels. In spite of these promising results, further studies need to be performed for a more complete and accurate assessment of the graft function after transplantation.
Finally, EVNMP of discarded human pancreata has been successfully demonstrated relatively recently by two groups despite none of the organs being either transplanted or undergoing islet isolation protocol. Barlow et al. adapted their kidney EVNMP technique to initiate EVNMP of four non-transplantable pancreases (50). A red blood cell-based perfusate mixture was diluted with Gelofusine as colloid plus additives (sodium bicarbonate, mannitol, glucose, and heparin). All organs demonstrated adequate perfusion, pancreatic exocrine function, and insulin production. Histopathology demonstrated varying degrees of damage, reflective of the heterogeneous features of pancreas donor, ranging from focal to extended acinar necrosis. Arterial pressure was maintained at 50-55 mmHg, which could be considered high. Furthermore, the incorporation of a dialysis unit to the system or the addition of antiproteases to the perfusate are two potential factors that could help reduce pancreas injury.
The translational study published by Hamaoui et al. (47) applied the protocols developed in porcine models to three humans' pancreata. As mentioned before, the EVNMP circuit was designed for functional assessment of the pancreas after maintaining the graft in hypothermic conditions, i.e, its applicability is therefore limited.
Nassar et al. (51) utilized a modified liver perfusion machine for three DBD donor human pancreases. Perfusion times were longer (6–12 h) compared to Barlow et al. (1–2 h) but CIT was much lower (4 vs. 13 h in the study of Barlow et al.). Results revealed endocrine function at both 6- and 12-h through the determination of C-peptide production and by chromogranin staining. At the end of perfusion, histology showed well-preserved cell architecture without necrosis or hemorrhage in 2 out of 3 pancreases. Taken together, both studies show that EVNMP of discarded human donor pancreata is potentially achievable and allows cell injury and functional evaluation.
Despite the difficulty of making firm conclusions from the research findings on pancreas EVNMP, which are based strictly on published data, it seems at this point feasible to recommend the use of lower arterial pressure to avoid endothelial injury while achieving higher flow rates to allow a better perfusion.
From the studies, we have also concluded that perfusate-containing packed red blood cells improve outcomes when compared to whole blood perfusate. Thus, a red blood cell-based perfusate solution with adequate oxygenation (95%) and supplemented with antiprotease, colloid, antibiotics and heparin may provide a prolonged preservation of the pancreas grafts. More studies are needed to assess the usefulness of other red blood cell-based perfusates combined with artificial acellular solutions.
Regarding the time of perfusion, it is challenging to set a range but one may consider that, when using longer periods of perfusion, the use of a dialysis circuit may help to reduce edema formation and recirculation of metabolic toxins.
Nevertheless, to date, and with these limited publications in pancreas EVNMP, there are no clear, approved, and accurate conditions to enable its implementation on a routine basis in pancreatic clinical settings. Significant refinements to the technique and rigorous analysis of data from larger studies are urgently required. Obviously, we would also need further perfusion studies with transplanted grafts to corroborate that the promising findings related to the suitability of the EVNMP system can be reproduced in a clinical model.
Conclusion
Although the number of extended criteria donor organ transplantation has increased, there has been minor progression in the development of a proper quality assessment for these organs. At present, the EVNMP technique allows organ monitoring and estimation of its quality before transplantation, unlike clinical pancreas transplantation, for which there are few experimental and pre-clinical studies published.
Outcome measures in current studies of EVNMP-treated pancreas include blood flow, blood gas analysis (acid-base homeostasis, pH, bicarbonate, and oxygen consumption), mean arterial pressure, endocrine function under glucose stimulation, amylase and lipase levels, production of pancreatic secretion, metabolic markers, and histologic analysis. There is still disagreement concerning the optimal parameters such as the set of perfusion pressures or flow rates to enable an optimal post-transplant pancreatic graft function. In that vein, the lack of accurate pre-clinical methodological design may lead to errors in the analysis of results, affecting the quality of the research and thus contribute to the frequent scarcity of reliable animal studies.
Funding
This study has been supported by Instituto de Salud Carlos III (ISCIII) through the Project PI18/00161 and co-funded by the European Union awarded to JF-F. This work has been supported by grant from the Ministerio de Ciencia, Innovación y Universidades, reference PID2019-104130RB-I00 awarded to EF-P. AL-L was recipient of a Grant (Ayudas para contratos predoctorales para la formación de doctores convocatoria 2020; Reference PRE2020-096502) funded by the Ministerio de Ciencia e Innovación (MICINN).
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Statements
Data availability statement
The original contributions presented in the study are included in the article/supplementary materials, further inquiries can be directed to the corresponding author.
Author contributions
Study conception and design: JF-F and JF. Data acquisition, analysis, and interpretation: JF-F, EF-P, AL-L, and RG-P. Drafting of manuscript and critical revision of manuscript: JF-F, EF-P, AL-L, RG-P, and JF. All authors agree to be accountable for the content of the work. All authors contributed to the article and approved the submitted version.
Acknowledgments
We thank Steve Illing, RSA CELTA, for English Language Assistance.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1.
CasanovaD. en nombre de Grupo Español de Trasplante de Páncreas. Pancreas transplantation: 50 years of experience. Cir Esp. (2017) 95:254–60. 10.1016/j.ciresp.2017.02.005
2.
KandaswamyRStockPGMillerJSkeansMAWhiteJWainrightJet al. OPTN/SRTR 2019 annual data report: pancreas. Am J Transplant. (2021) 21 (Suppl. 2):138–207. 10.1111/ajt.16496
3.
AnazawaTOkajimaHMasuiTUemotoS. Current state and future evolution of pancreatic islet transplantation. Ann Gastroenterol Surg. (2018) 3:34–42. 10.1002/ags3.12214
4.
DholakiaSOskrochiYEastonGPapaloisV. Advances in pancreas transplantation. J R Soc Med. (2016) 109:141–6. 10.1177/0141076816636369
5.
BenjamensSLeemkuilMMargreiterCHuurmanVALeuveninkHGPolRAet al. steady decline in pancreas transplantation rates. Pancreatology. (2019) 19:31–8. 10.1016/j.pan.2018.11.003
6.
GiorgakisEMathurAKChakkeraHAReddyKSMossAASingerAL. Solid pancreas transplant: Pushing forward. World J Transplant. (2018) 8:237–51. 10.5500/wjt.v8.i7.237
7.
ParenteAOsei-BordomDCRoncaVPereraMTPRMirzaD. Organ restoration with normothermic machine perfusion and immune reaction. Front Immunol. (2020) 11:565616. 10.3389/fimmu.2020.565616
8.
PrudhommeTKervellaDLe Bas-BernardetSCantarovichDKaramGBlanchoGet al. Ex situ perfusion of pancreas for whole-organ transplantation: is it safe and feasible? A systematic review. J Diabetes Sci Technol. (2020) 14:120–34. 10.1177/1932296819869312
9.
BelliniMID'AndreaV. Organ preservation: which temperature for which organ?J Int Med Res. (2019) 47:2323–5. 10.1177/0300060519833889
10.
WuMYYiangGTLiaoWTTsaiAPChengYLChengPWet al. Current mechanistic concepts in ischemia and reperfusion injury. Cell Physiol Biochem. (2018) 46:1650–67. 10.1159/000489241
11.
PetrenkoACarnevaleMSomovAOsorioJRodríguezJGuibertEet al. Organ preservation into the 2020s: the era of dynamic intervention. Transfus Med Hemother. (2019) 46:151–72. 10.1159/000499610
12.
Ferrer-FàbregaJFolch-PuyELozanoJJVentura-AguiarPCárdenasGParedesDet al. Current trends in organ preservation solutions for pancreas transplantation: a single-center retrospective study. Transpl Int. (2022) 28:10419. 10.3389/ti.2022.10419
13.
Van RaemdonckDNeyrinckARegaFDevosTPirenneJ. Machine perfusion in organ transplantation: a tool for ex-vivo graft conditioning with mesenchymal stem cells?Curr Opin Organ Transplant. (2013) 18:24–33. 10.1097/MOT.0b013e32835c494f
14.
HosgoodSAThompsonEMooreTWilsonCHNicholsonML. Normothermic machine perfusion for the assessment and transplantation of declined human kidneys from donation after circulatory death donors. Br J Surg. (2018) 105:388–94. 10.1002/bjs.10733
15.
NasrallaDCoussiosCCMergentalHAkhtarMZButlerAJCeresaCDLet al. Consortium for organ preservation in Europe. A randomized trial of normothermic preservation in liver transplantation. Nature. (2018) 557:50–6. 10.1038/s41586-018-0047-9
16.
CypelMYeungJCDonahoeLChenMZamelRHoetzeneckerKet al. Normothermic ex vivo lung perfusion: does the indication impact organ utilization and patient outcomes after transplantation?J Thorac Cardiovasc Surg. (2019) S0022-5223(19)31732-5. 10.1016/j.jtcvs.2019.06.123
17.
PrudhommeTMulveyJFYoungLAJMesnardBLo FaroMLOgbemudiaAEet al. Ischemia-reperfusion injuries assessment during pancreas preservation. Int J Mol Sci. (2021) 22:5172. 10.3390/ijms22105172
18.
GasteigerSBerchtoldVBösmüllerCDostalLUlmerHBogenspergerCet al. A retrospective propensity score matched analysis reveals superiority of hypothermic machine perfusion over static cold storage in deceased donor kidney transplantation. J Clin Med. (2020) 9:2311. 10.3390/jcm9072311
19.
TingleSJFigueiredoRSMoirJAGoodfellowMThompsonERIbrahimIKet al. Hypothermic machine perfusion is superior to static cold storage in deceased donor kidney transplantation: a meta-analysis. Clin Transplant. (2020) 34:e13814. 10.1111/ctr.13814
20.
MichelSGLa Muraglia GM2ndMadariagaMLTitusJSSeligMKFarkashEAet al. Preservation of donor hearts using hypothermic oxygenated perfusion. Ann Transplant. (2014) 19:409–16. 10.12659/AOT.890797
21.
DoppenbergJBLeemkuilMEngelseMAKrikkeCde KoningEJPLeuveninkHGD. Hypothermic oxygenated machine perfusion of the human pancreas for clinical islet isolation: a prospective feasibility study. Transpl Int. (2021) 34:1397–407. 10.1111/tri.13927
22.
HamaouiKPapaloisV. Machine perfusion and the pancreas: will it increase the donor pool?Curr Diab Rep. (2019) 19:56. 10.1007/s11892-019-1165-y
23.
SerifisNMathesonRCloonanDRickertCGMarkmannJFCoeTM. Machine perfusion of the liver: a review of clinical trials. Front Surg. (2021) 8:625394. 10.3389/fsurg.2021.625394
24.
FardAPearsonRLathanRMarkPBClancyMJ. Perfusate composition and duration of ex-vivo normothermic perfusion in kidney transplantation: a systematic review. Transpl Int. (2022) 35:10236. 10.3389/ti.2022.10236
25.
HarperSHosgoodSKayMNicholsonM. Leucocyte depletion improves renal function during reperfusion using an experimental isolated haemoperfused organ preservation system. Br J Surg. (2006) 93:623–9. 10.1002/bjs.5324
26.
HosgoodSASaeb-ParsyKWilsonCCallaghanCCollettDNicholsonML. Protocol of a randomised controlled, open-label trial of ex vivo normothermic perfusion versus static cold storage in donation after circulatory death renal transplantation. BMJ Open. (2017) 7:e012237. 10.1136/bmjopen-2016-012237
27.
MergentalHLaingRWKirkhamAJPereraMTPRBoteonYLAttardJet al. Transplantation of discarded livers following viability testing with normothermic machine perfusion. Nat Commun. (2020) 11:2939. 10.1038/s41467-020-16251-3
28.
BabkinBPStarlingEH. A method for the study of the perfused pancreas. J Physiol. (1926) 61:245–7. 10.1113/jphysiol.1926.sp002286
29.
AndersonELongJA. The effect of hyperglycemia on insulin secretion as determined with the isolated rat pancreas in a perfusion apparatus. Endocrinology. (1947) 40:92–7. 10.1210/endo-40-2-92
30.
NardiLGreepJM. Chambers DA, Mccrae C, Skinner DB. Physiologic peregrinations in pancreatic perfusion. Ann Surg. (1963) 158:830–9. 10.1097/00000658-196311000-00012
31.
Hermon-TaylorJA. technique for perfusion of the isolated canine pancreas. Responses to secretin and gastrin. Gastroenterology. (1968) 55:488–501. 10.1016/S0016-5085(19)34025-9
32.
RaoMMElmslieRG. A modified technic of isolated pancreatic perfusion. J Surg Res. (1970) 10:357–62. 10.1016/S0022-4804(70)80004-X
33.
AugierDBoucardJPPascalJPRibetAVaysseN. Relationships between blood flow and secretion in the isolated perfused canine pancreas. J Physiol. (1972) 221:55–69. 10.1113/jphysiol.1972.sp009738
34.
EloyJK. Pousse A, Dauchel J, Grenier JF. Ex vivo vascular perfusion of the isolated canine pancreas Experimental procedure, haemodynamic data and experimental applications. Eur Surg Res. (1974) 6:341–53. 10.1159/000127741
35.
MurphyJJ. Proceedings: Secretory response of the haemoperfused isolated canine pancreas. J Physiol. (1974) 236:20P–1P.
36.
MurphyJJMcGeeneyKFDawsonCFitzGeraldOFitzGeraldP. The isolated haemoperfused canine pancreas: an experimental model. Ir J Med Sci. (1977) 146:39–43. 10.1007/BF03030926
37.
SahariaPMargolisSZuidemaGDCameronJL. Acute pancreatitis with hyperlipemia: studies with an isolated perfused canine pancreas. Surgery. (1977) 82:60–7.
38.
EckhauserFKnolJAPorter-FinkVLockeryDEdgcombLStrodelWEet al. Ex vivo normothermic hemoperfusion of the canine pancreas: applications and limitations of a modified experimental preparation. J Surg Res. (1981) 31:22–37. 10.1016/0022-4804(81)90026-3
39.
PeggDEKlempnauerJDiaperMPTaylorMJ. Assessment of hypothermic preservation of the pancreas in the rat by a normothermic perfusion assay. J Surg Res. (1982) 33:194–200. 10.1016/0022-4804(82)90029-4
40.
BroePJZuidemaGDCameronJL. The role of ischemia in acute pancreatitis: studies with an isolated perfused canine pancreas. Surgery. (1982) 91:377–82.
41.
O'MalleyVPKeyesDMPostierRG. The fluosol-perfused isolated canine pancreas: a model for the study of blood component effects in acute pancreatitis. J Surg Res. (1986) 40:210–5. 10.1016/0022-4804(86)90153-8
42.
WahlbergJSouthardJHBelzerFO. Preservation-induced pancreatitis in an isolated perfused pancreas model in the dog. Transpl Int. (1989) 2:165–7. 10.1007/BF02414603
43.
ClemensJAOlsonJCameronJL. Cerulein-induced pancreatitis in the ex vivo isolated perfused canine pancreas. Surgery. (1991) 109:515–22.
44.
NordbackIHClemensJACameronJL. The role of cholecystokinin in the pathogenesis of acute pancreatitis in the isolated pancreas preparation. Surgery. (1991) 109:301–6.
45.
KuanKGWeeMNChungWYKumarRMeesSTDennisonAet al. A study of normothermic hemoperfusion of the porcine pancreas and kidney. Artif Organs. (2017) 41:490–5. 10.1111/aor.12770
46.
KumarRChungWYRunauFIsherwoodJDKuanKGWestKet al. Ex vivo normothermic porcine pancreas: a physiological model for preservation and transplant study. Int J Surg. (2018) 54:206–15. 10.1016/j.ijsu.2018.04.057
47.
HamaouiKGowersSSandhuBVallantNCookTBoutelleMet al. Development of pancreatic machine perfusion: translational steps from porcine to human models. J Surg Res. (2018) 223:263–74. 10.1016/j.jss.2017.11.052
48.
OgbemudiaAEHakimGDenguFEl-GilaniFDumbillRMulveyJet al. Development of ex situ normothermic reperfusion as an innovative method to assess pancreases after preservation. Transpl Int. (2021) 34:1630–42. 10.1111/tri.13990
49.
MazilescuLIParmentierCKalimuthuSNGaneshSKawamuraMGotoTet al. Normothermic ex situ pancreas perfusion for the preservation of porcine pancreas grafts. Am J Transplant. (2022) 22:1339–49. 10.1111/ajt.17019
50.
BarlowADHamedMOMallonDHBraisRJGribbleFMScottMAet al. Use of ex vivo normothermic perfusion for quality assessment of discarded human donor pancreases. Am J Transplant. (2015) 15:2475–82. 10.1111/ajt.13303
51.
NassarALiuQWalshMQuintiniC. Normothermic ex vivo perfusion of discarded human pancreas. Artif Organs. (2018) 42:334–5. 10.1111/aor.12985
52.
BelliniMIYiuJNozdrinMPapaloisV. The effect of preservation temperature on liver, kidney, and pancreas tissue ATP in animal and preclinical human models. J Clin Med. (2019) 8:1421. 10.3390/jcm8091421
Summary
Keywords
experimental—animal models, ischemia-reperfusion injury, normothermic pancreas perfusion, organ preservation, pancreas transplantation
Citation
Ferrer-Fàbrega J, Folch-Puy E, Llaves-López A, García-Pérez R and Fuster J (2022) Breaking the limits of experimental pancreas transplantation: Working toward the clinical ideal graft. Front. Transplant. 1:1035480. doi: 10.3389/frtra.2022.1035480
Received
02 September 2022
Accepted
27 September 2022
Published
21 October 2022
Volume
1 - 2022
Edited by
Kojiro Nakamura, Kyoto University, Japan
Reviewed by
Thomas Prudhomme, Centre Hospitalier Universitaire de Toulouse, France
Updates
Copyright
© 2022 Ferrer-Fàbrega, Folch-Puy, Llaves-López, García-Pérez and Fuster.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Joana Ferrer-Fàbrega joferrer@clinic.cat
†These authors have contributed equally to this work and share first authorship
This article was submitted to Organ and Tissue Preservation, a section of the journal Frontiers in Transplantation
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.